10 Biggest Gainers of Last Week

3. Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA)

Despite news of losing the bid against Amneal Pharmaceuticals and having to remove incorrect patents for an inhaler product, shares of Teva recorded an increase of 33.79 percent in the past trading week, ending Friday at $22.09 from $16.51 registered on Monday.

The rise followed an announcement that the company’s Duvakitug drug, developed with French pharmaceutical company Sanofi (SNY), met its primary goals to treat ulcerative colitis and Crohn’s disease.

Last year, the two companies announced their collaboration to develop treatments for inflammatory bowel disease (IBD), with hopes that the drug could achieve blockbuster status, generating at least $1 billion in annual sales.